Clinical trials: in Belarus
Von Willebrand Disease
Study of Biostate® in Children With Von Willebrand Disease
This is an open-label study to investigate the pharmacokinetics (PK), efficacy, and safety of a von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, in children with Von Willebrand disease (VWD) in whom treatment with a VWF…
- Trial name
- NCT01213446
- Testing
- Biostate
- Where
- 7 sites in Belarus, Georgia and 4 more
- Volunteers
- 17 people
- Sponsor
- CSL Behring
Cachexia, Non-Small Cell Lung Cancer
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01395914
- Testing
- Anamorelin HCl
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 513 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Hemophilia A
Study of Biostate® in Children With Hemophilia A
The objective of this study is to assess the efficacy and safety of a Von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, and to investigate the pharmacokinetics of Biostate in children with haemophilia A.
- Trial name
- NCT01229007
- Testing
- Biostate
- Where
- 8 sites in Belarus, Georgia and 4 more
- Volunteers
- 35 people
- Sponsor
- CSL Behring
Ulcerative Colitis
Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative…
- Trial name
- NCT01059344
- Testing
- Mesalamin
- Where
- 31 sites in Belarus, India and 2 more
- Volunteers
- 281 people
- Sponsor
- Tillotts Pharma AG
Heart Septal Defects, Ventricle, Heart Defects, Congenital
Genes Causing Ebstein's Anomaly
This study will investigate Ebstein's anomaly, a congenital abnormality of the tricuspid valve of the heart and try to identify the genetic origins of the disease.
- Conditions
- Heart Septal Defects, Ventricle, Heart Defects, Congenital, Double Outlet Right Ventricle, Truncus Arteriosus, Persistent
- Trial name
- NCT00497705
- Where
- 3 sites in United States, Belarus and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
Primary Objectives: Part A (dose ranging study): To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks.
- Trial name
- RA-MOBILITY (NCT01061736)
- Testing
- Sarilumab, Methotrexate, Folic Acid
- Where
- 262 sites in United States, Argentina and 34 more
- Volunteers
- 1,675 people
- Sponsor
- Sanofi
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A…
- Trial name
- NCT02020369
- Testing
- Coagulation Factor VIIa (Recombinant)
- Where
- 17 sites in United States, Belarus and 8 more
- Volunteers
- 27 people
- Sponsor
- rEVO Biologics
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Rheumatoid Arthritis
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis
- Trial name
- BIORA (NCT01759030)
- Testing
- Rituximab
- Where
- 40 sites in Belarus, India and 2 more
- Volunteers
- 181 people
- Sponsor
- Biocad
Angina Pectoris
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable…
- Trial name
- CAESA (NCT01659580)
- Testing
- T89 high dose, T89 Low dose, Sanqi+Bingpian
- Where
- 94 sites in United States, Belarus and 5 more
- Volunteers
- 1,004 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Early Allograft Dysfunction, Ischemic Reperfusion Injury
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing…
- Conditions
- Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation, Hyperfibrinolysis
- Trial name
- PATAC (NCT01887171)
- Testing
- Tacrolimus
- Where
- Belarus
- Volunteers
- 86 people
- Sponsor
- Republican Scientific and Practical Center for Organ and Tissue Transplantation
Systemic Lupus Erythematosus
CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administered in addition to standard therapy in subjects with active Systemic Lupus Erythematosus (SLE) disease as defined by…
- Trial name
- CHABLIS-SC1 (NCT01395745)
- Testing
- blisibimod
- Where
- 90 sites in Belarus, Brazil and 14 more
- Volunteers
- 442 people
- Sponsor
- Anthera Pharmaceuticals
Recurrent or Persistent Endometrial Carcinoma
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent…
- Trial name
- NCT02064725
- Testing
- Sodium cridanimod
- Where
- 21 sites in United States, Belarus and 3 more
- Volunteers
- 8 people
- Sponsor
- Kevelt AS
Newly Diagnosed Multiple Myeloma
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
- Trial name
- NCT00405756
- Testing
- Lenalidomide: Double-blind Induction, Melphalan, Prednisone
- Where
- 98 sites in Australia, Austria and 20 more
- Volunteers
- 459 people
- Sponsor
- Celgene Corporation
Liver Transplantation, Reperfusion
A Study of Retrograde rEperfusion in Dbd Donor LIver Transplantation
To evaluate whether retrograde caval reperfusion of liver graft could be superior over antegrade portal reperfusion in regard of incidence and severity of early allograft liver dysfunction.
- Conditions
- Liver Transplantation, Reperfusion, Delayed Graft Function
- Trial name
- REDLIT (NCT02423941)
- Testing
- Retrogade reperfusion, Antegrade reperfusion
- Where
- Belarus
- Volunteers
- 90 people
- Sponsor
- Republican Scientific and Practical Center for Organ and Tissue Transplantation
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Ventricular Arrhythmias
Acute Subcutaneous Defibrillation
To assess the defibrillation efficacy of a subcutaneous defibrillation system.
- Trial name
- ASQ (NCT01771172)
- Where
- 8 sites in Belarus, Denmark and 3 more
- Volunteers
- 50 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.
- Trial name
- TOWER (NCT00751881)
- Testing
- Teriflunomide
- Where
- 193 sites in United States, Australia and 24 more
- Volunteers
- 1,169 people
- Sponsor
- Sanofi